Related Experiment Videos
Prognosis for pedunculated hepatocellular carcinoma.
1Second Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Oncology
|July 8, 1999
Summary
Pedunculated hepatocellular carcinoma (HCC) shows a poor prognosis, especially without early surgical resection. Survival is comparable to intermediate-sized tumors but worse than small tumors, with high early mortality.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Pedunculated hepatocellular carcinoma (HCC) is a rare variant.
- Its distinct growth pattern may influence prognosis.
- Limited data exists on its survival outcomes compared to conventional HCC.
Purpose of the Study:
- To compare the survival outcomes of pedunculated HCC with conventional HCC based on tumor size.
- To evaluate the impact of different treatment modalities on pedunculated HCC survival.
Main Methods:
- Retrospective analysis of 13 institutional cases and 163 reported cases of pedunculated HCC.
- Comparison with conventional HCC groups (A: <2cm, B: 2-5cm, C: >5cm).
- Analysis of survival based on treatment: surgical resection, transcatheter arterial embolization (TAE), transcatheter arterial infusion chemotherapy (TACI), and conservative management.
Main Results:
- Pedunculated HCC survival was similar to Group B (<5cm) but worse than Group A (<2cm) and better than Group C (>5cm).
- Surgically treated pedunculated HCC patients showed significantly higher survival rates than those treated with TAE, TACI, or conservative management.
- 42% of pedunculated HCC patients died within 1 year; most cases exhibited moderately or poorly differentiated histology.
Conclusions:
- Pedunculated HCC generally has an unfavorable prognosis due to its rapid progression.
- Early surgical resection is crucial for improving survival in pedunculated HCC.
- Timely intervention is essential, as conservative or less invasive treatments yield poorer outcomes.